Abivax (ABVX) said Sunday that results from two clinical trials showed that a 50 milligram daily dose regimen of its potential moderate-to-severely active ulcerative colitis treatment obefazimod met its primary endpoint of clinical remission at week eight.
The company said all key secondary efficacy endpoints were also met in the trials, which enrolled 1,272 patients.
In pooled data from the trials, no signals of serious or severe infections or malignancies were observed, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments